StockData

Biogen vs Neurocrine Biosciences

BIIB and NBIX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BIIB and NBIX compare

Biogen is the larger company, worth 2.2 times as much as Neurocrine Biosciences ($37.1B against $16.9B).

On earnings, Neurocrine Biosciences is cheaper: it trades at 24.3× trailing earnings, against 107× for Biogen.

Neurocrine Biosciences grew revenue faster over the last twelve months (34.4% versus 2.3% for Biogen).

Neurocrine Biosciences keeps more of each dollar of sales as profit, with a net margin of 20.9% compared with 3.4% at Biogen.

Neurocrine Biosciences scores higher on the StockData Score (19 against 4 for Biogen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBIIBNBIX
Size and price
Market cap$37.1B$16.9B
Share price$250.79$165.92
Change, 1 year49.7%14.5%
Change, 5 years3.2%90.8%
Beta (5Y)0.140.29
Employees7,5001,800
StockData Score
Total score419 (better)
Valuation score13 (better)
Growth score05 (better)
Performance score15 (better)
Health score26 (better)
Dividend score00
Valuation
P/E107×24.3× (better)
P/S3.6× (better)5.0×
P/B–4.6×
EV/EBITDA21.9×20.7× (better)
P/FCF17.9× (better)19.4×
PEG–0.55
FCF yield5.6% (better)5.2%
Fair value$160.54$176.61
Margin of safety−56.2%6.1% (better)
Growth
Revenue growth (TTM)2.3%34.4% (better)
Revenue growth, 5Y average−6.0%22.3% (better)
Net income growth (TTM)−78.4%103% (better)
EPS growth (TTM)−78.7%102% (better)
EPS growth, 5Y average−18.7%2.3% (better)
Profitability
Gross margin74.0%98.0% (better)
Operating margin–23.6%
Net margin3.4%20.9% (better)
FCF margin20.1%25.8% (better)
Return on equity–22.1%
Return on invested capital–23.7%
Financial health
Debt / equity–0.00
Current ratio1.95 (better)1.87
Altman Z-score3.077.55 (better)
Piotroski F-score47 (better)
Dividends and buybacks
Buyback yield–−0.74%
Shareholder yield0.00% (better)−0.74%
Ownership
Held by institutions96.2%99.5%
Held by insiders0.21%1.2%
Insider net buying, 12 months−$905K (better)−$74.4M
Superinvestors holding1–
Short interest, % of float3.7%5.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.